{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-099336","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.988647+00:00","generated_at":"2026-05-15T17:06:27.889516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rapport Therapeutics reports FY2025 net loss $111.5M, RAP-219 Phase 2 positive, Phase 3 Q2 2026","bullets":["Net loss Q4 2025 $33.8M, full year $111.5M; R&D expenses $94.8M FY2025 vs $60.9M FY2024.","Cash, equivalents, short-term investments $490.5M at Dec 31, 2025; runway into H2 2029.","RAP-219 Phase 2a in focal onset seizures met primary endpoints: 77.8% median reduction in clinical seizure frequency.","Phase 3 program for RAP-219 in FOS accelerated to Q2 2026; open-label safety trial enrolling.","Entered Tenacia collaboration for Greater China: $20M upfront, up to $308M milestones plus tiered royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-099336","json":"https://secwatch.observer/filing/0001193125-26-099336.json","markdown":"https://secwatch.observer/filing/0001193125-26-099336.md","text":"https://secwatch.observer/filing/0001193125-26-099336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/0001193125-26-099336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/rapp-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:06:27.889516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bfa8e831e4fdd6125e31864e43038426b99b133","claim":"Rapport Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2025.","evidence_excerpt":"On March 10, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/0001193125-26-099336-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}